



Advancing Transfusion and  
Cellular Therapies Worldwide

## **Centers for Medicare & Medicaid Services Proposes Medicare Hospital Outpatient Payment Rates and Policies for CY 2020; Proposes to Exclude Blood Centers from the Laboratory Date of Service Policy Exception**

On July 29, the Centers for Medicare & Medicaid Services (CMS) released a [proposed rule](#) updating Medicare payment rates and policies under the hospital outpatient prospective payment system (OPPS) and the ambulatory surgical center payment system for calendar year 2020. Significant proposals for the transfusion medicine and cellular therapy community include: (1) proposed payment policies and rates for CY 2020; (2) modifications to the laboratory date of service policy exception, including a proposed exclusion for blood centers and blood banks; (3) price transparency requirements; and (4) proposals to expedite beneficiaries' access to innovative technologies. Comments are due to CMS on September 27, 2019.

### **Proposed Payment Policies and Rates for Transfusion Medicine and Cellular Therapies**

Consistent with the methodology used since 2005, CMS proposes to continue establishing separate payment rates for blood and blood products using a blood-specific cost-to-charge ratio (CCR) methodology, which uses actual or simulated CCRs from the most recently available hospital cost reports to convert hospital charges for blood and blood products to costs. CMS proposes to continue applying the blood-specific CCR methodology when calculating the costs of blood and blood products that appear on claims with services assigned to comprehensive ambulatory payment classifications (C-APCs). A C-APC is “a classification for the provision of a primary service and all adjunctive services provided to support the delivery of the primary service.” Since the costs of blood and blood products are reflected in the overall costs of the C-APCs and the proposed payment rates of the C-APCs, CMS is proposing not to make separate payments for blood and blood products when they appear on the same claims as services assigned to the C-APCs.

CMS proposes to increase payment rates for most blood products. In prior years, CMS established an interim payment rate for pathogen-reduced platelets (P9073) based on a crosswalk to existing code P9037 (platelets, pheresis, leukocytes reduced, irradiated, each unit). For CY 2020, CMS proposes to calculate the payment rate for P9073 by using claims payment history. As a result, CMS' proposed payment rate for P9073 is \$600.87, which is 3.9 percent lower than the final CY 2019 payment. The agency also proposes to reduce payments for apheresis platelets (P9034), cryoprecipitate reduced plasma (P9044), donor retested fresh frozen plasma (P9060) and pathogen-reduced pooled plasma (P9070). Please see Table 1 for a summary of the proposed payment rates for blood and blood products.

As summarized in Table 2, CMS proposes to increase the payment rates for most transfusion, apheresis and stem cell procedures covered by the OPPS. Similarly, CMS proposes to increase payments for most transfusion laboratory services. In the preamble to the proposed rule, CMS proposes to reassign the code for pathogen tests for platelets (P9100) from New Technology APC 1493 (New Technology – Level 1C (\$21 - \$30) to New Technology APC 1494



(New Technology – Level 1D (\$31 - \$40)). Therefore, the proposed payment rate for P9100 is \$35.50, which is higher than the \$25.50 payment rate finalized for CY 2019. Please see Table 3 for a summary of the proposed payment rates for transfusion laboratory services.

CMS notes that the chimeric antigen receptor (CAR) T-cell therapies (Q2041 (Axicabtagene ciloleucel car+) and Q2042 (Tisagenlecleucel car-pos t)) will continue to have pass-through payment status during CY 2020. Table 4 summarizes the proposed payment rates for CAR T-cell therapies.

### **Modifications to the Laboratory Date of Service Policy Exception**

All Medicare claims for laboratory services must include the date of service (DOS), which impacts billing and payment requirements. In 2018, CMS finalized an exception to the DOS policy, which would require a performing laboratory to bill Medicare directly for advanced diagnostic laboratory tests (ADLTs) and molecular pathology tests provided to beneficiaries furnished services under the OPSS when certain requirements are satisfied.

CMS has not yet implemented the 2018 DOS policy exception due to concerns raised by stakeholders, including AABB. Significantly, in the 2020 OPSS proposed rule CMS proposes three potential changes to the 2018 DOS policy exception, including: (1) excluding blood banks and blood centers from the DOS policy exception; (2) excluding molecular pathology tests from the DOS policy exception; and (3) having the ordering physician determine whether the results of an ADLT or molecular pathology test are intended to guide treatment provided during a hospital inpatient encounter, which will inform the DOS and the billing requirements. If finalized, these policies would enable blood centers to continue billing hospitals for ADLTs and molecular pathology tests.

- **Exclusion for Blood Centers and Blood Banks:** CMS proposes to revise the laboratory date of service policy to exclude blood banks and centers from the laboratory DOS exception. Therefore, the DOS for “laboratory testing performed by blood banks and centers on specimens collected from a hospital outpatient during a hospital outpatient encounter would, depending on the underlying service, be the date of specimen collection. As a result, the hospital would bill for the laboratory test under arrangements and the blood bank or center performing the test would seek payment from the hospital.”

CMS proposes to define “blood bank or blood center” for the purpose of this exception as “an entity whose primary function is the collection, storage and dissemination of blood products,” and notes that these entities are typically accredited by AABB. The agency reasons that molecular pathology testing performed by blood banks and blood centers is for the purpose of blood compatibility testing, rather than for diagnostic purposes. As a result, “molecular pathology testing, when performed by blood banks or centers, is inherently tied to a hospital service because hospitals receive payment for and/or use the blood and/or blood products provided by blood banks and blood centers to treat patients



in the hospital setting. Accordingly, [CMS] believes that such testing is so connected to the treatment furnished to the patient in the hospital that it must be considered a hospital service and that hospitals should be permitted to bill and receive payment for such testing performed on these blood and/or blood-related products.”

CMS is specifically soliciting feedback on how a blood bank and blood center should be defined for the purpose of this provision, and how to distinguish blood banks and blood centers from other laboratories.

- **Exclusion of Molecular Pathology Tests:** CMS is considering revising the laboratory DOS policy exception for the hospital outpatient setting to limit the exception to tests designated by CMS as ADLTs. CMS defines an ADLT as “a [clinical diagnostic laboratory test] covered under Medicare Part B that is offered and furnished only by a single laboratory, and cannot be sold for use by a laboratory other than the single laboratory that designed the test or a successor owner.” An ADLT must be cleared or approved by the Food and Drug Administration (FDA) or be “an analysis of multiple biomarkers of deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or proteins; when combined with an empirically derived algorithm, yields a result that predicts the probability a specific individual patient will develop a certain condition(s) or respond to a particular therapy(ies); provides new clinical diagnostic information that cannot be obtained from any other test or combination of tests; and may include other assays.” If finalized, this proposal would enable hospitals to bill Medicare directly for molecular pathology tests performed for patients in the hospital outpatient setting, and laboratories could seek payment from the hospital.
- **Purpose of Laboratory Results:** CMS proposes that ordering physicians should determine whether the results of the ADLT or molecular pathology test are intended to guide treatment provided during a hospital outpatient encounter. If the ordering physician determines that the results of the laboratory test are intended to guide treatment during a hospital outpatient encounter, the DOS would be the date of specimen collection, the hospital that collected the specimen would bill for the laboratory test under arrangements and the laboratory would seek payment from the hospital for the test. Conversely, if the ordering physician determines that the test results are not intended to guide treatment during the hospital outpatient encounter from which the specimen was collected or during a future hospital outpatient encounter, the DOS of the test would be the date of test performance, the test would not be considered a hospital service and the performing laboratory would be required to bill for the test.

### **Price Transparency Requirements**

CMS proposes several policies related to price transparency and requiring hospitals to make publicly available their standard charges for all items and services. The proposed rule



Advancing Transfusion and  
Cellular Therapies Worldwide

includes (1) definitions for “hospital”, “standard charges”, and “items and services”; (2) requirements for making public a machine-readable file online that includes all standard charges for all hospital items and services; (3) requirements for making public payer-specific negotiated charges for a limited set of “shoppable services” that are displayed and packaged in a consumer-friendly manner; and (4) monitoring and enforcement provisions.

### **Access to Innovative Technologies**

CMS proposes policies intended to expedite Medicare beneficiaries’ access to innovative technologies. CMS proposes to create an alternative outpatient pass-through pathway for devices that are part of FDA’s Breakthrough Devices Program and have received FDA marketing authorization (i.e., PMA; 510(k) clearance; or the granting of a De Novo classification request). These devices would not be evaluated under the current substantial clinical improvement criterion for the purposes of determining device pass-through payment status. In addition, CMS is soliciting comments on the Agency’s approach for determining whether a device qualifies for an OPPS transitional pass-through payment because it offers “substantial clinical improvement” when compared to existing devices.

\* \* \* \* \*

AABB will be submitting comments to CMS on the proposed rule. If you have any feedback that you would like for AABB to consider or if you have any questions on the proposed rule, please email [govt\\_and\\_legal@aabb.org](mailto:govt_and_legal@aabb.org).



Advancing Transfusion and  
Cellular Therapies Worldwide

**Table 1. Blood and Blood Products**

| HCPCS Code | Short Descriptor                                   | 2020 SI | 2019 APC                                                                             | 2020 APC | Final 2019 Payment | Proposed 2020 Payment | \$ Change 2019-2020 | % Change 2019-2020 |
|------------|----------------------------------------------------|---------|--------------------------------------------------------------------------------------|----------|--------------------|-----------------------|---------------------|--------------------|
| P9010      | Whole blood for transfusion                        | R       | 9510                                                                                 | 9510     | \$111.18           | \$116.47              | \$5.29              | 4.8%               |
| P9011      | Blood split unit                                   | R       | 9520                                                                                 | 9520     | \$126.06           | \$143.55              | \$17.49             | 13.9%              |
| P9012      | Cryoprecipitate each unit                          | R       | 9511                                                                                 | 9511     | \$49.40            | \$50.94               | \$1.54              | 3.1%               |
| P9016      | Rbc leukocytes reduced                             | R       | 9512                                                                                 | 9512     | \$184.78           | \$194.55              | \$9.77              | 5.3%               |
| P9017      | Plasma 1 donor frz w/in 8 hr                       | R       | 9508                                                                                 | 9508     | \$71.53            | \$88.49               | \$16.96             | 23.7%              |
| P9019      | Platelets, each unit                               | R       | 9515                                                                                 | 9515     | \$107.96           | \$115.15              | \$7.19              | 6.7%               |
| P9020      | Platelet rich plasma unit                          | R       | 9516                                                                                 | 9516     | \$125.23           | \$135.37              | \$10.14             | 8.1%               |
| P9021      | Red blood cells unit                               | R       | 9517                                                                                 | 9517     | \$140.12           | \$143.98              | \$3.86              | 2.8%               |
| P9022      | Washed red blood cells unit                        | R       | 9518                                                                                 | 9518     | \$355.93           | \$377.77              | \$21.84             | 6.1%               |
| P9023      | Frozen plasma, pooled, sd                          | R       | 9509                                                                                 | 9509     | \$75.96            | \$84.31               | \$8.35              | 11.0%              |
| P9031      | Platelets leukocytes reduced                       | R       | 9526                                                                                 | 9526     | \$136.61           | \$139.12              | \$2.51              | 1.8%               |
| P9032      | Platelets, irradiated                              | R       | 9500                                                                                 | 9500     | \$171.91           | \$182.75              | \$10.84             | 6.3%               |
| P9033      | Platelets leukoreduced irradiated                  | R       | 9521                                                                                 | 9521     | \$167.14           | \$218.11              | \$50.97             | 30.5%              |
| P9034      | Platelets, pheresis                                | R       | 9507                                                                                 | 9507     | \$337.08           | \$325.05              | -\$12.03            | -3.6%              |
| P9035      | Platelet pheresis leukoreduced                     | R       | 9501                                                                                 | 9501     | \$486.30           | \$515.52              | \$29.22             | 6.0%               |
| P9036      | Platelet pheresis irradiated                       | R       | 9502                                                                                 | 9502     | \$552.91           | \$757.14              | \$204.23            | 36.9%              |
| P9037      | Platelet pheresis leukoreduced irradiated          | R       | 9530                                                                                 | 9530     | \$624.93           | \$659.54              | \$34.61             | 5.5%               |
| P9038      | Rbc irradiated                                     | R       | 9505                                                                                 | 9505     | \$221.36           | \$241.38              | \$20.02             | 9.0%               |
| P9039      | Rbc deglycerolized                                 | R       | 9504                                                                                 | 9504     | \$331.14           | \$343.43              | \$12.29             | 3.7%               |
| P9040      | Rbc leukoreduced irradiated                        | R       | 9522                                                                                 | 9522     | \$255.58           | \$272.31              | \$16.73             | 6.5%               |
| P9043      | Plasma protein fraction, 5%, 50ml                  | R       | 9514                                                                                 | 9514     | \$26.95            | \$18.45               | -\$8.50             | -31.5%             |
| P9044      | Cryoprecipitate reduced plasma                     | R       | 9523                                                                                 | 9523     | \$88.73            | \$99.45               | \$10.72             | 12.1%              |
| P9048      | Plasma protein fraction, 5%, 250ml                 | R       | 9519                                                                                 | 9519     | \$76.98            | \$106.90              | \$29.92             | 38.9%              |
| P9050      | Granulocytes, pheresis unit                        | E2      | Not paid by Medicare when submitted on outpatient claims (any outpatient bill type). |          |                    |                       |                     |                    |
| P9051      | Blood, l/r, cmv-neg                                | R       | 9524                                                                                 | 9524     | \$175.94           | \$190.41              | \$14.47             | 8.2%               |
| P9052      | Platelets, hla-m, l/r, unit                        | R       | 9525                                                                                 | 9525     | \$844.83           | \$852.22              | \$7.39              | 0.9%               |
| P9053      | Platelet, pheresis, l/r cmv-neg, irradiated        | R       | 9531                                                                                 | 9531     | \$492.31           | \$523.49              | \$31.18             | 6.3%               |
| P9054      | Blood, l/r, frozen/deglycerolized/washed           | R       | 9527                                                                                 | 9527     | \$298.37           | \$335.52              | \$37.15             | 12.5%              |
| P9055      | Platelet, apheresis, l/r, cmv-neg                  | R       | 9528                                                                                 | 9528     | \$445.06           | \$513.34              | \$68.28             | 15.3%              |
| P9056      | Blood, l/r, irradiated                             | R       | 9529                                                                                 | 9529     | \$225.47           | \$215.14              | -\$10.33            | -4.6%              |
| P9057      | Rbc, frozen/deglycerolized/washed, l/r, irradiated | R       | 9532                                                                                 | 9532     | \$224.51           | \$273.03              | \$48.52             | 21.6%              |
| P9058      | Rbc, l/r, cmv-neg, irradiated                      | R       | 9533                                                                                 | 9533     | \$229.29           | \$251.13              | \$21.84             | 9.5%               |
| P9059      | Plasma, frozen between 8-24 hours                  | R       | 9513                                                                                 | 9513     | \$76.66            | \$78.72               | \$2.06              | 2.7%               |



Advancing Transfusion and  
Cellular Therapies Worldwide

**Table 1. Blood and Blood Products**

| <b>HCPCS Code</b> | <b>Short Descriptor</b>      | <b>2020 SI</b> | <b>2019 APC</b> | <b>2020 APC</b> | <b>Final 2019 Payment</b> | <b>Proposed 2020 Payment</b> | <b>\$ Change 2019-2020</b> | <b>% Change 2019-2020</b> |
|-------------------|------------------------------|----------------|-----------------|-----------------|---------------------------|------------------------------|----------------------------|---------------------------|
| P9060             | Fr frz plasma donor retested | R              | 9503            | 9503            | \$62.81                   | \$51.35                      | -\$11.46                   | -18.2%                    |
| P9070             | Pathogen reduced plasma pool | R              | 9534            | 9534            | \$41.43                   | \$30.36                      | -\$11.07                   | -26.7%                    |
| P9071             | Pathogen reduced plasma sing | R              | 9535            | 9535            | \$78.35                   | \$99.33                      | \$20.98                    | 26.8%                     |
| P9073             | Platelets pheresis path redu | R              | 9536            | 9536            | \$624.93                  | \$600.87                     | -\$24.06                   | -3.9%                     |



Advancing Transfusion and  
Cellular Therapies Worldwide

**Table 2. Transfusion, Apheresis, and Stem Cell Procedures**

| HCPCS Code | Short Descriptor               | 2020 SI | 2019 APC             | 2020 APC | Final 2019 Payment | Proposed 2020 Payment | \$ Change 2019-2020 | % Change 2019-2020 |
|------------|--------------------------------|---------|----------------------|----------|--------------------|-----------------------|---------------------|--------------------|
| 36430      | Blood transfusion service      | S       | 5241                 | 5241     | \$382.90           | \$392.66              | \$9.76              | 2.5%               |
| 36440      | Bl push transfuse 2 yr/<       | S       | 5241                 | 5241     | \$382.90           | \$392.66              | \$9.76              | 2.5%               |
| 36450      | Bl exchange/transfuse nb       | S       | 5241                 | 5241     | \$382.90           | \$392.66              | \$9.76              | 2.5%               |
| 36455      | Bl exchange/transfuse non-nb   | S       | 5241                 | 5241     | \$382.90           | \$392.66              | \$9.76              | 2.5%               |
| 36456      | Prtl exchange transfuse nb     | S       | 5241                 | 5241     | \$382.90           | \$392.66              | \$9.76              | 2.5%               |
| 36460      | Transfusion service fetal      | S       | 5241                 | 5241     | \$382.90           | \$392.66              | \$9.76              | 2.5%               |
| 36511      | Apheresis wbc                  | S       | 5242                 | 5242     | \$1,247.00         | \$1,317.51            | \$70.51             | 5.7%               |
| 36512      | Apheresis rbc                  | S       | 5242                 | 5242     | \$1,247.00         | \$1,317.51            | \$70.51             | 5.7%               |
| 36513      | Apheresis platelets            | S       | 5241                 | 5241     | \$382.90           | \$392.66              | \$9.76              | 2.5%               |
| 36514      | Apheresis plasma               | S       | 5242                 | 5242     | \$1,247.00         | \$1,317.51            | \$70.51             | 5.7%               |
| 36516      | Apheresis immunoads slctv      | S       | 5243                 | 5243     | \$3,922.50         | \$3,831.85            | -\$90.65            | -2.3%              |
| 36522      | Photopheresis                  | S       | 5243                 | 5243     | \$3,922.50         | \$3,831.85            | -\$90.65            | -2.3%              |
| 38205      | Harvest allogeneic stem cell   | B       | Not paid under OPPS. |          |                    |                       |                     |                    |
| 38206      | Harvest auto stem cells        | S       | 5242                 | 5242     | \$1,247.00         | \$1,317.51            | \$70.51             | 5.7%               |
| 38207      | Cryopreserve stem cells        | S       | 5241                 | 5241     | \$382.90           | \$392.66              | \$9.76              | 2.5%               |
| 38208      | Thaw preserved stem cells      | S       | 5241                 | 5241     | \$382.90           | \$392.66              | \$9.76              | 2.5%               |
| 38209      | Wash harvest stem cells        | S       | 5241                 | 5241     | \$382.90           | \$392.66              | \$9.76              | 2.5%               |
| 38210      | T-cell depletion of harvest    | S       | 5241                 | 5241     | \$382.90           | \$392.66              | \$9.76              | 2.5%               |
| 38211      | Tumor cell deplete of harvest  | S       | 5241                 | 5241     | \$382.90           | \$392.66              | \$9.76              | 2.5%               |
| 38212      | Rbc depletion of harvest       | S       | 5241                 | 5241     | \$382.90           | \$392.66              | \$9.76              | 2.5%               |
| 38213      | Platelet deplete of harvest    | S       | 5241                 | 5241     | \$382.90           | \$392.66              | \$9.76              | 2.5%               |
| 38214      | Volume deplete of harvest      | S       | 5241                 | 5241     | \$382.90           | \$392.66              | \$9.76              | 2.5%               |
| 38215      | Harvest stem cell concentrate  | S       | 5241                 | 5241     | \$382.90           | \$392.66              | \$9.76              | 2.5%               |
| 38220      | Dx bone marrow aspirations     | J1      | 5072                 | 5072     | \$1,375.50         | \$1,457.06            | \$81.56             | 5.9%               |
| 38221      | Dx bone marrow biopsies        | J1      | 5072                 | 5072     | \$1,375.50         | \$1,457.06            | \$81.56             | 5.9%               |
| 38222      | Dx bone marrow bx & aspir      | J1      | 5072                 | 5072     | \$1,375.50         | \$1,457.06            | \$81.56             | 5.9%               |
| 38230      | Bone marrow harvest allogeneic | S       | 5242                 | 5242     | \$1,247.00         | \$1,317.51            | \$70.51             | 5.7%               |
| 38232      | Bone marrow harvest autolog    | S       | 5243                 | 5243     | \$3,922.50         | \$3,831.85            | -\$90.65            | -2.3%              |
| 38240      | Transplnt allo hct/donor       | J1      | 5244                 | 5244     | \$37,892.76        | \$41,276.66           | \$3,383.90          | 8.9%               |
| 38241      | Transplnt autol hct/donor      | S       | 5242                 | 5242     | \$1,247.00         | \$1,317.51            | \$70.51             | 5.7%               |
| 38242      | Transplnt allo lymphocytes     | S       | 5242                 | 5242     | \$1,247.00         | \$1,317.51            | \$70.51             | 5.7%               |
| 38243      | Transplj hematopoietic boost   | S       | 5242                 | 5242     | \$1,247.00         | \$1,317.51            | \$70.51             | 5.7%               |
| 88184      | Flowcytometry/ tc 1 marker     | Q2      | 5673                 | 5673     | \$274.22           | \$296.44              | \$22.22             | 8.1%               |



Advancing Transfusion and  
Cellular Therapies Worldwide

**Table 2. Transfusion, Apheresis, and Stem Cell Procedures**

| <b>HCPCS Code</b> | <b>Short Descriptor</b>   | <b>2020 SI</b> | <b>2019 APC</b>                                                                                                    | <b>2020 APC</b> | <b>Final 2019 Payment</b> | <b>Proposed 2020 Payment</b> | <b>\$ Change 2019-2020</b> | <b>% Change 2019-2020</b> |
|-------------------|---------------------------|----------------|--------------------------------------------------------------------------------------------------------------------|-----------------|---------------------------|------------------------------|----------------------------|---------------------------|
| 88185             | Flowcytometry/tc add-on   | N              | Paid under OPPS; payment is packaged into payment for other services. Therefore, there is no separate APC payment. |                 |                           |                              |                            |                           |
| 88187             | Flowcytometry/read 2-8    | B              | Not paid under OPPS.                                                                                               |                 |                           |                              |                            |                           |
| 88188             | Flowcytometry/read 9-15   | B              | Not paid under OPPS.                                                                                               |                 |                           |                              |                            |                           |
| 88189             | Flowcytometry/read 16 & > | B              | Not paid under OPPS.                                                                                               |                 |                           |                              |                            |                           |





Advancing Transfusion and  
Cellular Therapies Worldwide

**Table 3. Transfusion Laboratory Services**

| <b>HCPCS Code</b> | <b>Short Descriptor</b>      | <b>2020 SI</b> | <b>2019 APC</b> | <b>2020 APC</b> | <b>Final 2019 Payment</b> | <b>Proposed 2020 Payment</b> | <b>\$ Change 2019-2020</b> | <b>% Change 2019-2020</b> |
|-------------------|------------------------------|----------------|-----------------|-----------------|---------------------------|------------------------------|----------------------------|---------------------------|
| 86850             | Rbc antibody screen          | Q1             | 5671            | 5671            | \$50.98                   | \$50.54                      | -\$0.44                    | -0.9%                     |
| 86860             | Rbc antibody elution         | Q1             | 5672            | 5672            | \$144.73                  | \$148.62                     | \$3.89                     | 2.7%                      |
| 86870             | Rbc antibody identification  | Q2             | 5673            | 5673            | \$274.22                  | \$296.44                     | \$22.22                    | 8.1%                      |
| 86880             | Coombs test direct           | Q1             | 5732            | 5732            | \$32.12                   | \$34.33                      | \$2.21                     | 6.9%                      |
| 86885             | Coombs test indirect qual    | Q1             | 5672            | 5672            | \$144.73                  | \$148.62                     | \$3.89                     | 2.7%                      |
| 86886             | Coombs test indirect titer   | Q1             | 5672            | 5672            | \$144.73                  | \$148.62                     | \$3.89                     | 2.7%                      |
| 86890             | Autologous blood process     | Q1             | 5672            | 5672            | \$144.73                  | \$148.62                     | \$3.89                     | 2.7%                      |
| 86891             | Autologous blood op salvage  | Q1             | 5674            | 5674            | \$558.12                  | \$631.35                     | \$73.23                    | 13.1%                     |
| 86900             | Blood typing serologic abo   | Q1             | 5734            | 5734            | \$106.48                  | \$109.98                     | \$3.50                     | 3.3%                      |
| 86901             | Blood typing serologic rh(d) | Q1             | 5732            | 5732            | \$32.12                   | \$34.33                      | \$2.21                     | 6.9%                      |
| 86902             | Blood type antigen donor ea  | Q1             | 5673            | 5673            | \$274.22                  | \$296.44                     | \$22.22                    | 8.1%                      |
| 86904             | Blood typing patient serum   | Q1             | 5732            | 5732            | \$32.12                   | \$34.33                      | \$2.21                     | 6.9%                      |
| 86905             | Blood typing rbc antigens    | Q1             | 5673            | 5673            | \$274.22                  | \$296.44                     | \$22.22                    | 8.1%                      |
| 86906             | Bld typing serologic rh phnt | Q1             | 5732            | 5732            | \$32.12                   | \$34.33                      | \$2.21                     | 6.9%                      |
| 86920             | Compatibility test spin      | Q1             | 5672            | 5672            | \$144.73                  | \$148.62                     | \$3.89                     | 2.7%                      |
| 86921             | Compatibility test incubate  | Q1             | 5672            | 5672            | \$144.73                  | \$148.62                     | \$3.89                     | 2.7%                      |
| 86922             | Compatibility test antiglob  | Q1             | 5672            | 5672            | \$144.73                  | \$148.62                     | \$3.89                     | 2.7%                      |
| 86923             | Compatibility test electric  | Q1             | 5672            | 5672            | \$144.73                  | \$148.62                     | \$3.89                     | 2.7%                      |
| 86927             | Plasma fresh frozen          | S              | 5672            | 5672            | \$144.73                  | \$148.62                     | \$3.89                     | 2.7%                      |
| 86930             | Frozen blood prep            | Q1             | 5673            | 5673            | \$274.22                  | \$296.44                     | \$22.22                    | 8.1%                      |
| 86931             | Frozen blood thaw            | Q1             | 5673            | 5673            | \$274.22                  | \$296.44                     | \$22.22                    | 8.1%                      |



**Table 3. Transfusion Laboratory Services**

| <b>HCPCS Code</b>  | <b>Short Descriptor</b>       | <b>2020 SI</b> | <b>2019 APC</b> | <b>2020 APC</b> | <b>Final 2019 Payment</b> | <b>Proposed 2020 Payment</b> | <b>\$ Change 2019-2020</b> | <b>% Change 2019-2020</b> |
|--------------------|-------------------------------|----------------|-----------------|-----------------|---------------------------|------------------------------|----------------------------|---------------------------|
| 86932              | Frozen blood freeze/thaw      | Q1             | 5732            | 5732            | \$32.12                   | \$34.33                      | \$2.21                     | 6.9%                      |
| 86945              | Blood product/irradiation     | Q1             | 5732            | 5732            | \$32.12                   | \$34.33                      | \$2.21                     | 6.9%                      |
| 86950              | Leukocyte transfusion         | Q1             | 5672            | 5672            | \$144.73                  | \$148.62                     | \$3.89                     | 2.7%                      |
| 86960              | Vol reduction of blood/prod   | Q1             | 5672            | 5672            | \$144.73                  | \$148.62                     | \$3.89                     | 2.7%                      |
| 86965              | Pooling blood platelets       | Q1             | 5672            | 5672            | \$144.73                  | \$148.62                     | \$3.89                     | 2.7%                      |
| 86970              | Rbc pretx incubatj w/chemical | Q1             | 5732            | 5732            | \$32.12                   | \$34.33                      | \$2.21                     | 6.9%                      |
| 86971              | Rbc pretx incubatj w/enzymes  | Q1             | 5673            | 5673            | \$274.22                  | \$296.44                     | \$22.22                    | 8.1%                      |
| 86972              | Rbc pretx incubatj w/density  | Q1             | 5672            | 5672            | \$144.73                  | \$148.62                     | \$3.89                     | 2.7%                      |
| 86975              | Rbc serum pretx incubj drugs  | Q1             | 5732            | 5734            | \$32.12                   | \$109.98                     | \$77.86                    | 242.4%                    |
| 86976              | Rbc serum pretx id dilution   | Q1             | 5731            | 5731            | \$17.17                   | \$23.57                      | \$6.40                     | 37.3%                     |
| 86977              | Rbc serum pretx incubj/inhib  | Q1             | 5672            | 5672            | \$144.73                  | \$148.62                     | \$3.89                     | 2.7%                      |
| 86978              | Rbc pretreatment serum        | Q1             | 5732            | 5732            | \$32.12                   | \$34.33                      | \$2.21                     | 6.9%                      |
| 86985              | Split blood or products       | Q1             | 5672            | 5672            | \$144.73                  | \$148.62                     | \$3.89                     | 2.7%                      |
| 86999              | Transfusion procedure         | Q1             | 5731            | 5731            | \$17.17                   | \$23.57                      | \$6.40                     | 37.3%                     |
| P9100 <sup>1</sup> | Pathogen test for platelets   | S              | 1493            | 1494            | \$25.50                   | \$35.50                      | \$10.00                    | 39.2%                     |

<sup>1</sup> This table reflects CMS' proposal to reassign code P9100 to New Technology APC 1494, with a proposed payment rate of \$35.50. This proposal was included to the preamble to the proposed rule, but was not reflected in Appendix B.



Advancing Transfusion and  
Cellular Therapies Worldwide

**Table 4. CAR T-Cell Therapies**

| <b>HCPCS Code</b> | <b>Short Descriptor</b>      | <b>2020 SI</b> | <b>2019 APC</b> | <b>2020 APC</b> | <b>Final 2019 Payment</b> | <b>Proposed 2020 Payment</b> | <b>\$ Change 2019-2020</b> | <b>% Change 2019-2020</b> |
|-------------------|------------------------------|----------------|-----------------|-----------------|---------------------------|------------------------------|----------------------------|---------------------------|
| Q2041             | Axicabtagene ciloleucel car+ | G              | 9035            | 9035            | \$395,380.000             | \$395,380.00                 | \$0.00                     | 0.0%                      |
| Q2042             | Tisagenlecleucel car-pos t   | G              | 9194            | 9194            | \$439,388.31              | \$449,128.31                 | \$9,740.00                 | 2.2%                      |